Clopidogrel plus aspirin vs oral anticoagulation for atrial fibrillation: the ACTIVE W trial.
DeSilvey
Dennis L
DL
Waldo Cardiovascular Medicine, Belfast, ME 04915, USA. dldesilvey@wchi.com
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D000077144:Clopidogrel; D005260:Female; D006801:Humans; D000077405:Irbesartan; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020521:Stroke / Q000209:etiology / Q000517:prevention & control*; D013777:Tetrazoles / Q000627:therapeutic use*; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D000925:Anticoagulants; D001713:Biphenyl Compounds; D010975:Platelet Aggregation Inhibitors; D013777:Tetrazoles; D000077144:Clopidogrel; D000077405:Irbesartan; D013988:Ticlopidine; D001241:Aspirin